InvestorsHub Logo
Followers 14
Posts 737
Boards Moderated 0
Alias Born 09/13/2013

Re: None

Wednesday, 01/13/2016 7:23:57 AM

Wednesday, January 13, 2016 7:23:57 AM

Post# of 50669
Biotech Exec Took A Company From $2 to $14, Before Starting On This New Deal

Oxis has built a robust pipeline of clinical and preclinical candidates by licensing intellectual property from MultiCell Immunotherapeutics (MCIT), University of Minnesota and University of Pittsburgh. The company has cleaned up their cap structure through a financial restructuring and carried out a reverse stock split, effective December 15th, 2016 [3].

http://www.baystreet.ca/articles/stockstowatch.aspx?articleid=24342